-
ATNM Dashboard
- Financials
- Filings
-
Holdings
-
Transcripts
- ETFs
- Insider
-
Institutional
- Shorts
Actinium Pharmaceuticals (ATNM)
Company Profile
Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 78.98 mm | 78.98 mm | 78.98 mm | 78.98 mm | 78.98 mm | 78.98 mm |
Cash burn (monthly) | 2.46 mm | 358.83 k | 4.20 mm | 3.75 mm | 3.99 mm | 2.90 mm |
Cash used (since last report) | 9.91 mm | 1.45 mm | 16.93 mm | 15.10 mm | 16.09 mm | 11.69 mm |
Cash remaining | 69.08 mm | 77.54 mm | 62.05 mm | 63.88 mm | 62.89 mm | 67.29 mm |
Runway (months of cash) | 28.1 | 216.1 | 14.8 | 17.1 | 15.8 | 23.2 |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Nov 24 | June Sherie Almenoff | Stock Option Common Stock | Grant | Acquire A | No | No | 1.71 | 50,000 | 85.50 k | 50,000 |
28 Dec 23 | C. David Nicholson, | Stock Option Common Stock | Grant | Acquire A | No | No | 5 | 70,311 | 351.56 k | 70,311 |
28 Dec 23 | Jeffrey W. Chell | Stock Option Common Stock | Grant | Acquire A | No | No | 5 | 70,311 | 351.56 k | 70,311 |
28 Dec 23 | Steve O'Loughlin | Stock Option Common Stock | Grant | Acquire A | No | No | 5 | 253,123 | 1.27 mm | 253,123 |